Mezagitamab for kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- A biopsy of your kidney transplant shows active or chronic active antibody-mediated rejection (a type of rejection) that started more than 6 months after your transplant.
- You have certain antibodies (called DSA) in your blood that attack the donor kidney.
- Your kidney function is above a certain level (eGFR greater than 30).
- You have not had certain rejection treatments recently (like rituximab, bortezomib, eculizumab, IVIG, or plasmapheresis) within the last 6 months to 6 weeks.
- You do not have active infections (like hepatitis B, hepatitis C, HIV, or tuberculosis) or certain cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called felzartamab to see if it can help people who have a type of kidney inflammation after a transplant, even without donor-specific antibodies. It might offer a new treatment option for those who are not getting better on their own.
This study checks the long-term safety of felzartamab for people who have had a kidney transplant and are dealing with antibody-mediated rejection or signs of inflammation in the kidney. It's for those who were already in a previous study and took at least one dose of felzartamab.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Hear when a new Antibody-Mediated Rejection (AMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.